Glycopyrrolate/Formoterol Fumarate MDI Compared With Spiriva® as An Active Control in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

NCT01587079 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

159

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

DRUG: PT003
DRUG: PT001
DRUG: PT005
DRUG: Tiotropium inhalation powder

Sponsor

Pearl Therapeutics, Inc.